AbbVie Inc., through its subsidiary Allergan Aesthetics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval application for SKINVIVE by JUVÉDERM®. This application seeks to expand the indication of SKINVIVE to include the reduction of neck lines, aiming to improve neck appearance. Already approved in the U.S. for enhancing cheek skin smoothness in adults over 21, SKINVIVE by JUVÉDERM® could become the first hyaluronic acid injectable treatment option targeting neck lines if approved. The application is supported by a clinical study that met all primary and secondary endpoints.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。